The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor prognosis, particularly for patients with metastatic disease. Treatment for oligometastatic presentation has been reported in recent literature, but the role of intraperitoneal chemotherapy for patients with peritoneal metastases (PM) remains unclear. We performed a systematic literature search of the PubMed, Cochrane and Embase databases in order to identify clinical trials and case-series reporting on the safety and efficacy of intraperitoneal chemotherapy in patients with PDAC-derived PM. Eight publications reporting on 85 patients were identified, using three different therapeutic strategies. First, 37 patients received cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for PDAC with PM. Grade 3 and 4 complications occurred in 37.8% of patients, without perioperative mortality. Median disease-free survival and overall survival (OS) rates varied from 4 to 36 months and 4 to 62 months, respectively. Secondly, 40 patients with resectable PDAC without PM received prophylactic HIPEC following pancreatic resection, with postoperative morbidity and mortality rates of 30% and 5%, and 5-year OS rates of 23–24%. Finally, eight patients with PDAC-derived peritoneal disease were converted to resectable disease after receiving neoadjuvant intraperitoneal chemotherapy and operated on with curative intent, achieving a median OS of 27.8 months. In conclusion, CRS with HIPEC for PDAC-derived PM appears to be safe, conferring the same postoperative morbidity and mortality as reported on non-pancreatic malignancies. In highly selected patients, it could be considered for short-term disease control. However, long-term survival remains poor. The addition of prophylactic HIPEC for resectable PDAC cannot be recommended.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424

    Google Scholar 

  2. 2.

    Ilic M, Ilic I (2016) Epidemiology of pancreatic cancer. World J Gastroenterol 22(44):9694–9705

    PubMed  PubMed Central  Article  Google Scholar 

  3. 3.

    Rawla P, Sunkara T, Gaduputi V (2019) Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 10(1):10–27

    PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    De La Cruz MS, Young AP, Ruffin MT (2014) Diagnosis and management of pancreatic cancer. Am Fam Phys 89(8):626–632

    Google Scholar 

  5. 5.

    Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S (2006) Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 10(4):511–518

    PubMed  Article  PubMed Central  Google Scholar 

  6. 6.

    Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19):1817–1825

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703

    Article  CAS  Google Scholar 

  8. 8.

    De Ruysscher DPS, Oligometastases DC (2015). In: Peters S (ed) New therapeutic strategies in lung cancers. Springer, Cham

    Google Scholar 

  9. 9.

    Ghidini M, Petrillo A, Salati M, Khakoo S, Varricchio A, Tomasello G et al (2019) Surgery or locoregional approaches for hepatic oligometastatic pancreatic cancer: myth, hope, or reality? Cancers (Basel). 11:8

    Article  CAS  Google Scholar 

  10. 10.

    Sakaguchi T, Valente R, Tanaka K, Satoi S, Del Chiaro M (2019) Surgical treatment of metastatic pancreatic ductal adenocarcinoma: a review of current literature. Pancreatology 19(5):672–680

    PubMed  Article  Google Scholar 

  11. 11.

    Hackert T, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A et al (2017) Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol 43(2):358–363

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Yasukawa M, Kawaguchi T, Kawai N, Tojo T, Taniguchi S (2017) Surgical treatment for pulmonary metastasis of pancreatic ductal adenocarcinoma: study of 12 cases. Anticancer Res 37(10):5573–5576

    PubMed  Google Scholar 

  13. 13.

    Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L et al (2010) Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 116(24):5608–5618

    PubMed  Article  Google Scholar 

  14. 14.

    Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27(36):6237–6242

    PubMed  Article  Google Scholar 

  15. 15.

    Deraco M, Baratti D, Laterza B, Balestra MR, Mingrone E, Macri A et al (2011) Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol 37(1):4–9

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Brandl A, Yonemura Y, Glehen O, Sugarbaker PH, Rau B (2020) Long-term survival in patients with peritoneal metastasized gastric cancer treated with cytoreductive surgery and HIPEC: a multi-institutional cohort from PSOGI. J Clin Oncol 38(4):390

    Article  Google Scholar 

  17. 17.

    Honoré C, Goéré D, Macovei R, Colace L, Benhaim L, Elias D (2016) Peritoneal carcinomatosis from unusual cancer origins: is there a role for hyperthermic intraperitoneal chemotherapy? J Visc Surg 153(2):101–107

    PubMed  Article  Google Scholar 

  18. 18.

    Leigh N, Solomon D, Pletcher E, Labow DM, Magge DR, Sarpel U et al (2020) Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies? World J Surg Oncol 18(1):124

    PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Azzam AZ, Amin TM (2020) Combined Intraoperative Radiotherapy (IORT) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cytoreduction Surgery (CRS) as a Novel Approach in the Management of Resectable Pancreatic Cancer. Gulf J Oncol 1(33):19–26

    Google Scholar 

  20. 20.

    Tentes AA, Pallas N, Karamveri C, Kyziridis D, Hristakis C (2018) Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer. J Buon 23(2):482–487

    PubMed  Google Scholar 

  21. 21.

    Schwarz L, Levine EA, Morris D, Spiliotis J, Pocard M, Kianmanesh R et al (2018) CRS with HIPEC for peritoneal carcinomatosis of pancreatic adenocarcinoma. What do we expect? Results of a Multicenter International Study. HPB 20:S324

    Article  Google Scholar 

  22. 22.

    Farma JM, Pingpank JF, Libutti SK, Bartlett DL, Ohl S, Beresneva T et al (2005) Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion. J Gastrointest Surg 9(9):1346–1353

    PubMed  Article  Google Scholar 

  23. 23.

    Tentes AA, Stamou K, Pallas N, Karamveri C, Kyziridis D, Hristakis C (2016) The effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as an adjuvant in patients with resectable pancreatic cancer. Int J Hypertherm 32(8):895–899

    CAS  Article  Google Scholar 

  24. 24.

    Shiomi H, Naka S, Akabori H, Murakami K, Murata S, Yamamoto H et al (2014) Hyperthermic intraoperative intraperitoneal chemotherapy for advanced pancreatic cancer. HPB 16:610

    Article  Google Scholar 

  25. 25.

    Satoi S, Fujii T, Yanagimoto H, Motoi F, Kurata M, Takahara N et al (2017) Multicenter phase II study of intravenous and intraperitoneal paclitaxel with S-1 for pancreatic ductal adenocarcinoma patients with peritoneal metastasis. Ann Surg 265(2):397–401

    PubMed  Article  Google Scholar 

  26. 26.

    Yonemura Y, Canbay E, Li Y, Coccolini F, Glehen O, Sugarbaker PH et al (2016) A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol 42(8):1123–1131

    CAS  Article  Google Scholar 

  27. 27.

    Sugarbaker PH (1989) Surgical treatment of peritoneal carcinomatosis: 1988 Du Pont lecture. Can J Surg 32(3):164–170

    CAS  PubMed  Google Scholar 

  28. 28.

    Chua TC, Morris DL, Esquivel J (2010) Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 17(5):1330–1336

    PubMed  Article  Google Scholar 

  29. 29.

    Winer J, Zenati M, Ramalingam L, Jones H, Zureikat A, Holtzman M et al (2014) Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 21(5):1456–1462

    PubMed  Article  Google Scholar 

  30. 30.

    Yonemura Y, Canbay E, Ishibashi H (2013) Prognostic factors of peritoneal metastases from colorectal cancer following cytoreductive surgery and perioperative chemotherapy. Sci World J 2013:978394

    Article  Google Scholar 

  31. 31.

    Auer RC, Sivajohanathan D, Biagi J, Conner J, Kennedy E, May T (2020) Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review. Eur J Cancer 127:76–95

    PubMed  Article  PubMed Central  Google Scholar 

  32. 32.

    Goéré D, Passot G, Gelli M, Levine EA, Bartlett DL, Sugarbaker PH et al (2017) Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). Int J Hyperth 33(5):520–527

    Article  Google Scholar 

  33. 33.

    Thomassen I, Lemmens VE, Nienhuijs SW, Luyer MD, Klaver YL, de Hingh IH (2013) Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study. Pancreas 42(1):72–75

    PubMed  Article  PubMed Central  Google Scholar 

  34. 34.

    Takahara N, Isayama H, Nakai Y, Sasaki T, Saito K, Hamada T et al (2015) Pancreatic cancer with malignant ascites: clinical features and outcomes. Pancreas 44(3):380–385

    PubMed  PubMed Central  Google Scholar 

  35. 35.

    Jo JH, Chung MJ, Park JY, Bang S, Park SW, Chung JB et al (2014) Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea. Pancreas 43(7):1022–1031

    PubMed  Article  Google Scholar 

  36. 36.

    Clark CJ, Traverso LW (2010) Positive peritoneal lavage cytology is a predictor of worse survival in locally advanced pancreatic cancer. Am J Surg 199(5):657–662

    PubMed  Article  PubMed Central  Google Scholar 

  37. 37.

    Esquivel J, Sticca R, Sugarbaker P, Levine E, Yan TD, Alexander R et al (2007) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement Society of Surgical Oncology. Ann Surg Oncol 14(1):128–133

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Tewari M, Hazrah P, Kumar V, Shukla HS (2010) Options of restorative pancreaticoenteric anastomosis following pancreaticoduodenectomy: a review. Surg Oncol 19(1):17–26

    PubMed  Article  PubMed Central  Google Scholar 

  39. 39.

    Dubé P, Sideris L, Law C, Mack L, Haase E, Giacomantonio C et al (2015) Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms. Curr Oncol 22(2):e100–e112

    PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Downs-Canner S, Ding Y, Magge DR, Jones H, Ramalingam L, Zureikat A et al (2015) A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion. Ann Surg Oncol 22(5):1651–1657

    PubMed  Article  Google Scholar 

  41. 41.

    Doud AN, Randle RW, Clark CJ, Levine EA, Swett KR, Shen P et al (2015) Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 22(5):1645–1650

    PubMed  Article  Google Scholar 

  42. 42.

    Schwarz L, Votanopoulos K, Morris D, Yonemura Y, Deraco M, Piso P et al (2016) Is the combination of distal pancreatectomy and cytoreductive surgery with HIPEC reasonable? Results of an international multicenter study. Ann Surg 263(2):369–375

    PubMed  Article  Google Scholar 

  43. 43.

    Mizrahi JD, Surana R, Valle JW, Shroff RT (2020) Pancreatic cancer. Lancet 395(10242):2008–2020

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297(3):267–277

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  45. 45.

    Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10):1073–1081

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  46. 46.

    Goéré D, Glehen O, Quenet F, Guilloit JM, Bereder JM, Lorimier G et al (2020) Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol 21(9):1147–1154

    PubMed  Article  PubMed Central  Google Scholar 

  47. 47.

    Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers AGJ et al (2019) Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol 4(10):761–770

    PubMed  Article  PubMed Central  Google Scholar 

  48. 48.

    Sugarbaker PH (2017) Strategies to improve local control of resected pancreas adenocarcinoma. Surg Oncol 26(1):63–70

    PubMed  Article  PubMed Central  Google Scholar 

  49. 49.

    Ridwelski K, Meyer F, Hribaschek A, Kasper U, Lippert H (2002) Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurence of peritoneal carcinomatosis. J Surg Oncol 79(1):10–16

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  50. 50.

    Kamath A, Yoo D, Stuart OA, Bijelic L, Sugarbaker PH (2009) Rationale for an intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer. Recent Pat Anticancer Drug Discov 4(2):174–179

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    García Santos EP, Padilla Valverde D, Villarejo Campos P, Sánchez García S, Martín Fernández J (2018) HIPEC with gemcitabine as an adjuvant locoregional treatment after radical surgery in pancreatic cancer. Presentation of the clinical trial N-2016-004298-41. Pleura and Peritoneum. 3:sA206.

  52. 52.

    The Chicago Consensus on Peritoneal Surface Malignancies (2020) Management of Gastric Metastases. Ann Surg Oncol 27(6):1768–1773

    Article  Google Scholar 

  53. 53.

    Manzanedo I, Pereira F, Rihuete Caro C, Pérez-Viejo E, Serrano Á, Gutiérrez Calvo A et al (2019) Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Ann Surg Oncol 26(8):2615–2621

    PubMed  Article  Google Scholar 

Download references

Funding

None.

Author information

Affiliations

Authors

Contributions

AB and PK had the idea for the article; AB and MW performed the literature search and data analysis; AB, MW and MP drafted the manuscript and all authors critically revised the work. PK is guarantor for the project.

Corresponding author

Correspondence to Alexandre Brind’Amour.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Brind’Amour, A., Webb, M., Parapini, M. et al. The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review. Clin Exp Metastasis (2021). https://doi.org/10.1007/s10585-021-10074-2

Download citation

Keywords

  • Pancreatic ductal adenocarcinoma
  • PDAC
  • Peritoneal metastasis
  • Hyperthermic chemotherapy
  • Intraperitoneal chemotherapy
  • HIPEC